PMID: 9420025Jan 7, 1998Paper

Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality

Antimicrobial Agents and Chemotherapy
H MatsuoK Kubo

Abstract

We describe a new modality for administering aminoglycosides to hemodialysis (HD) patients, namely, a modification of the once-daily regimen which consists of administering the aminoglycosides over 60 min by drip infusion just before each HD session, with a preplanned peak concentration being reached at the beginning of the session and then with a rapidly decreasing concentration being achieved by the start of HD. The area under the concentration-time curve (AUC), i.e., the accumulation of the drug in the body, is thus minimized by this modality. Arbekacin (ABK) was given at a dose of 2 mg/kg of body weight to 10 HD patients infected with methicillin-resistant Staphylococcus aureus (MRSA) for 2 weeks (six sessions in total), resulting in the complete disappearance of MRSA in 5 patients. A high rate of elimination of ABK was attained for each patient while the patient was on HD (range, 0.20 to 0.42 h-1; mean 0.28 +/- 0.08 h-1) by using high-performance dialyzers provided with membranes made of either polymethylmethacrylate, cellulose triacetate (CTA), or ethylene vinyl alcohol. The best results were obtained with the CTA membrane, as revealed by the overall mass transfer coefficient (Ko). The AUC in the simulation model for the ...Continue Reading

References

Mar 1, 1991·Antimicrobial Agents and Chemotherapy·D N Gilbert
Jan 1, 1990·Chemotherapy·E YourassowskyF Crokaert
Apr 1, 1987·Antimicrobial Agents and Chemotherapy·J P FillastreS Josse
Mar 1, 1986·The Journal of Antimicrobial Chemotherapy·J E Kapusnik, M A Sande
Jun 1, 1995·The Journal of Antimicrobial Chemotherapy·J M Hamilton-Miller, S Shah
Aug 1, 1993·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·R Agarwal, R D Toto

❮ Previous
Next ❯

Citations

Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Osama Hussein Kamel MohamedMyrna Y Munar
Feb 1, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Kevin M SowinskiBruce A Mueller
Mar 20, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Alexandre BoyerNicholas Moore
Oct 27, 2006·Antimicrobial Agents and Chemotherapy·Yusuke TanigawaraKihachiro Shimizu
Oct 20, 2006·Journal of Clinical Pharmacology·Mette Maja B TeigenDavid W Johnson
Oct 19, 2014·Journal of Intensive Care Medicine·Susan J Lewis, Bruce A Mueller
Jan 9, 2004·Infectious Disease Clinics of North America·John Turnidge
Jul 3, 2007·Advances in Chronic Kidney Disease·Brian S DeckerKevin M Sowinski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.